UB Paderborn / Katalog / Suche / in CDI

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

The lancet oncology, 2018-12, Vol.19 (12), p.1641-1653

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparative analysis of PD‐1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL‐2 stimulation data

CPT: pharmacometrics and systems pharmacology, 2023-01, Vol.12 (1), p.87-94

2023

Link zum Volltext

Verfügbarkeit prüfen

Risk Factors for the Transmission of Methicillin-Resistant Staphylococcus aureus in an Adult Intensive Care Unit: Fitting a Model to the Data

The Journal of infectious diseases, 2002-02, Vol.185 (4), p.481-488

2002

Link zum Volltext

Verfügbarkeit prüfen

Understanding the Spread of Antibiotic Resistant Pathogens in Hospitals: Mathematical Models as Tools for Control

Clinical infectious diseases, 2001-11, Vol.33 (10), p.1739-1746

2001

Link zum Volltext

Verfügbarkeit prüfen

Vancomycin-Resistant Enterococci in Intensive-Care Hospital Settings: Transmission Dynamics, Persistence, and the Impact of Infection Control Programs

Proceedings of the National Academy of Sciences - PNAS, 1999-06, Vol.96 (12), p.6908-6913

1999

Link zum Volltext

Verfügbarkeit prüfen

Safety and Pharmacokinetics of the Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Administered by Intravenous Injection in Japanese and Caucasian Healthy Volunteers

Kansenshogaku Zasshi, 2022/03/20, Vol.96(2), pp.39-45

2022

Link zum Volltext

Verfügbarkeit prüfen

抗SARS-CoV-2モノクローナル抗体ソトロビマブの日本人・白人健康成人における静脈内点滴投与時の安全性及び薬物動態評価

感染症学雑誌, 2022/03/20, Vol.96(2), pp.39-45

2022

Link zum Volltext

Verfügbarkeit prüfen

Population Dose–Response‐Time Analysis of Itch Reduction and Patient‐Reported Tolerability Supports Phase III Dose Selection for Linerixibat

Clinical pharmacology and therapeutics, 2024-02, Vol.115 (2), p.288-298

2024

Link zum Volltext

Verfügbarkeit prüfen

Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial

Journal of allergy and clinical immunology, 2017-10, Vol.140 (4), p.1024-1031.e14

2017

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression

British journal of clinical pharmacology, 2021-02, Vol.87 (2), p.483-493

2021

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

Pediatric pulmonology, 2019-12, Vol.54 (12), p.1957-1967

2019

Link zum Volltext

Verfügbarkeit prüfen

Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome

Journal of pharmacokinetics and pharmacodynamics, 2020-06, Vol.47 (3), p.187-188

2020

Link zum Volltext

Verfügbarkeit prüfen

Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome

Clinical therapeutics, 2021-07, Vol.43 (7), p.1278-1280

2021

Link zum Volltext

Verfügbarkeit prüfen

Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study

Journal of hepatology, 2022-07, Vol.77, p.S873-S874

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection

Antiviral therapy, 2022-10, Vol.27 (5), p.135965352211311-13596535221131164

2022

Link zum Volltext

Verfügbarkeit prüfen

Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome

Journal of pharmacokinetics and pharmacodynamics, 2020-05, p.1

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections

Antimicrobial agents and chemotherapy, 2023-10, Vol.67 (10), p.e0053523-e0053523

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers

Clinical pharmacokinetics, 2024-01, Vol.63 (1), p.57-68

2024

Link zum Volltext

Verfügbarkeit prüfen

MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges

Clinical pharmacology and therapeutics, 2020-04, Vol.107 (4), p.762-772

2020

Link zum Volltext

Verfügbarkeit prüfen

Lost in translation? Bridging the preclinical / clinical divide

Malaria journal, 2012-10, Vol.11 (S1), p.P112-P112, Article P112

2012

Link zum Volltext

Verfügbarkeit prüfen

EP13-5. Dose responses for topical efficacy and systemic activity and relative therapeutic index for inhaled corticosteroid (ICS) in asthmatic subjects

Annals of The Japanese Respiratory Society, 2020-08, Vol.9 (suppl), p.344-344

2020

Link zum Volltext

Verfügbarkeit prüfen

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

Open forum infectious diseases, 2023-08, Vol.10 (8), p.ofad354-ofad354

2023

Link zum Volltext

Verfügbarkeit prüfen

Quantitative evaluation of biomarkers to assess efficacy of immunotherapy in inflammatory diseases (52.7)

The Journal of immunology (1950), 2011-04, Vol.186 (1_Supplement), p.52-52.7

2011

Link zum Volltext

Verfügbarkeit prüfen

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S353-S354

2021

Link zum Volltext

Verfügbarkeit prüfen

Antibody therapy reverses biological signatures of COVID-19 progression

Cell reports. Medicine, 2022-08, Vol.3 (8), p.100721-100721, Article 100721

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

Comparative analysis of PD‐1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL‐2 stimulation data

Risk Factors for the Transmission of Methicillin-Resistant Staphylococcus aureus in an Adult Intensive Care Unit: Fitting a Model to the Data

Understanding the Spread of Antibiotic Resistant Pathogens in Hospitals: Mathematical Models as Tools for Control

Vancomycin-Resistant Enterococci in Intensive-Care Hospital Settings: Transmission Dynamics, Persistence, and the Impact of Infection Control Programs

Safety and Pharmacokinetics of the Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Administered by Intravenous Injection in Japanese and Caucasian Healthy Volunteers

抗SARS-CoV-2モノクローナル抗体ソトロビマブの日本人・白人健康成人における静脈内点滴投与時の安全性及び薬物動態評価

Population Dose–Response‐Time Analysis of Itch Reduction and Patient‐Reported Tolerability Supports Phase III Dose Selection for Linerixibat

Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial

Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome

Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome

Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study

A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection

Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome

Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections

Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers

MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges

Lost in translation? Bridging the preclinical / clinical divide

EP13-5. Dose responses for topical efficacy and systemic activity and relative therapeutic index for inhaled corticosteroid (ICS) in asthmatic subjects

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

Quantitative evaluation of biomarkers to assess efficacy of immunotherapy in inflammatory diseases (52.7)

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Antibody therapy reverses biological signatures of COVID-19 progression

Suchergebnisse filtern